View in EDS

Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial.

Saved in:
Bibliographic Details
Title: Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial.
Authors: Qin S; Jinling Hospital of Nanjing University of Chinese Medicine, Nanjing, China., Chen M; Sun Yat-sen University Cancer Center, Guangzhou, China., Cheng AL; National Taiwan University Cancer Center and National Taiwan University Hospital, Taipei, Taiwan., Kaseb AO; The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Kudo M; Kindai University, Osaka, Japan., Lee HC; Department of Gastroenterology, Asan Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea., Yopp AC; Department of Surgery, Division of Surgical Oncology, The University of Texas Southwestern Medical Center, Dallas, TX, USA., Zhou J; Zhongshan Hospital, Fudan University, Shanghai, China., Wang L; Fudan University Shanghai Cancer Center, Shanghai, China., Wen X; 1st Hospital of Jilin University, Jilin, China., Heo J; College of Medicine, Pusan National University and Biomedical Research Institute, Pusan National University Hospital, Busan, South Korea., Tak WY; Kyungpook National University Hospital, School of Medicine, Kyungpook National University, Daegu, South Korea., Nakamura S; Himeji Red Cross Hospital, Hyogo, Japan., Numata K; Yokohama City University Medical Center, Yokohama, Japan., Uguen T; Hôpital de Pontchaillou, Rennes, France., Hsiehchen D; Department of Internal Medicine, Division of Hematology and Oncology, The University of Texas Southwestern Medical Center, Dallas, TX, USA., Cha E; Genentech, South San Francisco, CA, USA., Hack SP; Genentech, South San Francisco, CA, USA., Lian Q; Genentech, South San Francisco, CA, USA., Ma N; Genentech, South San Francisco, CA, USA., Spahn JH; Genentech, South San Francisco, CA, USA., Wang Y; Fudan University Shanghai Cancer Center, Shanghai, China; Genentech, South San Francisco, CA, USA., Wu C; Roche (China) Holding, Shanghai, China., Chow PKH; National Cancer Centre Singapore, Singapore; Duke-NUS Medical School, Singapore. Electronic address: pierce.chow@duke-nus.edu.sg.
Corporate Authors: IMbrave050 investigators
Source: Lancet (London, England) [Lancet] 2023 Nov 18; Vol. 402 (10415), pp. 1835-1847. Date of Electronic Publication: 2023 Oct 20.
Publication Type: Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase III; Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 2985213R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-547X (Electronic) Linking ISSN: 01406736 NLM ISO Abbreviation: Lancet Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 37871608
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Qin+S%22">Qin S</searchLink>; Jinling Hospital of Nanjing University of Chinese Medicine, Nanjing, China.<br /><searchLink fieldCode="AU" term="%22Chen+M%22">Chen M</searchLink>; Sun Yat-sen University Cancer Center, Guangzhou, China.<br /><searchLink fieldCode="AU" term="%22Cheng+AL%22">Cheng AL</searchLink>; National Taiwan University Cancer Center and National Taiwan University Hospital, Taipei, Taiwan.<br /><searchLink fieldCode="AU" term="%22Kaseb+AO%22">Kaseb AO</searchLink>; The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Kudo+M%22">Kudo M</searchLink>; Kindai University, Osaka, Japan.<br /><searchLink fieldCode="AU" term="%22Lee+HC%22">Lee HC</searchLink>; Department of Gastroenterology, Asan Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.<br /><searchLink fieldCode="AU" term="%22Yopp+AC%22">Yopp AC</searchLink>; Department of Surgery, Division of Surgical Oncology, The University of Texas Southwestern Medical Center, Dallas, TX, USA.<br /><searchLink fieldCode="AU" term="%22Zhou+J%22">Zhou J</searchLink>; Zhongshan Hospital, Fudan University, Shanghai, China.<br /><searchLink fieldCode="AU" term="%22Wang+L%22">Wang L</searchLink>; Fudan University Shanghai Cancer Center, Shanghai, China.<br /><searchLink fieldCode="AU" term="%22Wen+X%22">Wen X</searchLink>; 1st Hospital of Jilin University, Jilin, China.<br /><searchLink fieldCode="AU" term="%22Heo+J%22">Heo J</searchLink>; College of Medicine, Pusan National University and Biomedical Research Institute, Pusan National University Hospital, Busan, South Korea.<br /><searchLink fieldCode="AU" term="%22Tak+WY%22">Tak WY</searchLink>; Kyungpook National University Hospital, School of Medicine, Kyungpook National University, Daegu, South Korea.<br /><searchLink fieldCode="AU" term="%22Nakamura+S%22">Nakamura S</searchLink>; Himeji Red Cross Hospital, Hyogo, Japan.<br /><searchLink fieldCode="AU" term="%22Numata+K%22">Numata K</searchLink>; Yokohama City University Medical Center, Yokohama, Japan.<br /><searchLink fieldCode="AU" term="%22Uguen+T%22">Uguen T</searchLink>; Hôpital de Pontchaillou, Rennes, France.<br /><searchLink fieldCode="AU" term="%22Hsiehchen+D%22">Hsiehchen D</searchLink>; Department of Internal Medicine, Division of Hematology and Oncology, The University of Texas Southwestern Medical Center, Dallas, TX, USA.<br /><searchLink fieldCode="AU" term="%22Cha+E%22">Cha E</searchLink>; Genentech, South San Francisco, CA, USA.<br /><searchLink fieldCode="AU" term="%22Hack+SP%22">Hack SP</searchLink>; Genentech, South San Francisco, CA, USA.<br /><searchLink fieldCode="AU" term="%22Lian+Q%22">Lian Q</searchLink>; Genentech, South San Francisco, CA, USA.<br /><searchLink fieldCode="AU" term="%22Ma+N%22">Ma N</searchLink>; Genentech, South San Francisco, CA, USA.<br /><searchLink fieldCode="AU" term="%22Spahn+JH%22">Spahn JH</searchLink>; Genentech, South San Francisco, CA, USA.<br /><searchLink fieldCode="AU" term="%22Wang+Y%22">Wang Y</searchLink>; Fudan University Shanghai Cancer Center, Shanghai, China; Genentech, South San Francisco, CA, USA.<br /><searchLink fieldCode="AU" term="%22Wu+C%22">Wu C</searchLink>; Roche (China) Holding, Shanghai, China.<br /><searchLink fieldCode="AU" term="%22Chow+PKH%22">Chow PKH</searchLink>; National Cancer Centre Singapore, Singapore; Duke-NUS Medical School, Singapore. Electronic address: pierce.chow@duke-nus.edu.sg.
– Name: AuthorCorporate
  Label: Corporate Authors
  Group: Au
  Data: <searchLink fieldCode="CA" term="%22IMbrave050+investigators%22">IMbrave050 investigators</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%222985213R%22">Lancet (London, England)</searchLink> [Lancet] 2023 Nov 18; Vol. 402 (10415), pp. 1835-1847. <i>Date of Electronic Publication: </i>2023 Oct 20.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase III; Journal Article; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier%22">Elsevier </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>2985213R <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1474-547X (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2201406736%22">01406736 </searchLink><i>NLM ISO Abbreviation: </i>Lancet <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=37871608
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/S0140-6736(23)01796-8
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1835
    Titles:
      – TitleFull: Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Qin S
      – PersonEntity:
          Name:
            NameFull: Chen M
      – PersonEntity:
          Name:
            NameFull: Cheng AL
      – PersonEntity:
          Name:
            NameFull: Kaseb AO
      – PersonEntity:
          Name:
            NameFull: Kudo M
      – PersonEntity:
          Name:
            NameFull: Lee HC
      – PersonEntity:
          Name:
            NameFull: Yopp AC
      – PersonEntity:
          Name:
            NameFull: Zhou J
      – PersonEntity:
          Name:
            NameFull: Wang L
      – PersonEntity:
          Name:
            NameFull: Wen X
      – PersonEntity:
          Name:
            NameFull: Heo J
      – PersonEntity:
          Name:
            NameFull: Tak WY
      – PersonEntity:
          Name:
            NameFull: Nakamura S
      – PersonEntity:
          Name:
            NameFull: Numata K
      – PersonEntity:
          Name:
            NameFull: Uguen T
      – PersonEntity:
          Name:
            NameFull: Hsiehchen D
      – PersonEntity:
          Name:
            NameFull: Cha E
      – PersonEntity:
          Name:
            NameFull: Hack SP
      – PersonEntity:
          Name:
            NameFull: Lian Q
      – PersonEntity:
          Name:
            NameFull: Ma N
      – PersonEntity:
          Name:
            NameFull: Spahn JH
      – PersonEntity:
          Name:
            NameFull: Wang Y
      – PersonEntity:
          Name:
            NameFull: Wu C
      – PersonEntity:
          Name:
            NameFull: Chow PKH
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 18
              M: 11
              Text: 2023 Nov 18
              Type: published
              Y: 2023
          Identifiers:
            – Type: issn-electronic
              Value: 1474-547X
          Numbering:
            – Type: volume
              Value: 402
            – Type: issue
              Value: 10415
          Titles:
            – TitleFull: Lancet (London, England)
              Type: main
ResultId 1